---
title: "WAG GROUP CO | 10-Q: FY2025 Q2 Revenue: USD 16.72 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252105429.md"
datetime: "2025-08-07T20:51:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252105429.md)
  - [en](https://longbridge.com/en/news/252105429.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252105429.md)
---

# WAG GROUP CO | 10-Q: FY2025 Q2 Revenue: USD 16.72 M

Revenue: As of FY2025 Q2, the actual value is USD 16.72 M.

EPS: As of FY2025 Q2, the actual value is USD -0.12.

### Segment Revenue

-   **Total Revenues**: $16.72 million for the three months ended June 30, 2025, compared to $18.65 million for the same period in 2024, representing a decrease of 10.4%.
-   **Services Revenue**: $4.86 million for the three months ended June 30, 2025, compared to $5.58 million for the same period in 2024.
-   **Wellness Revenue**: $11.03 million for the three months ended June 30, 2025, compared to $11.55 million for the same period in 2024.
-   **Pet Food & Treats Revenue**: $0.84 million for the three months ended June 30, 2025, compared to $1.52 million for the same period in 2024.

### Operational Metrics

-   **Net Loss**: $6.15 million for the three months ended June 30, 2025, compared to $2.25 million for the same period in 2024, representing an increase of 173%.
-   **Total Costs and Expenses**: $21.33 million for the three months ended June 30, 2025, compared to $19.30 million for the same period in 2024, representing an increase of 10.5%.

### Cash Flow

-   **Net Cash Used in Operating Activities**: $1.25 million for the six months ended June 30, 2025, compared to $2.02 million for the same period in 2024.
-   **Net Cash Used in Investing Activities**: $0.60 million for the six months ended June 30, 2025, compared to $0.99 million for the same period in 2024.
-   **Net Cash Used in Financing Activities**: $1.10 million for the six months ended June 30, 2025, compared to $6.08 million for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is undergoing Chapter 11 bankruptcy proceedings and has filed a joint prepackaged plan of reorganization. The plan includes a restructuring support agreement with a debtor-in-possession loan facility of up to $6.5 million and an exit facility of up to $18.3 million.
-   **Non-Core Business**: The company sold its prescription management and digital e-prescribing software, Furscription, for $5.0 million, with $3.4 million of the proceeds used to pay down existing debt.
-   **Priority**: The company is focused on restructuring and emerging from Chapter 11, with plans subject to approval by the Bankruptcy Court.

### Related Stocks

- [PETXQ.US](https://longbridge.com/en/quote/PETXQ.US.md)

## Related News & Research

- [Telecom Stocks: What SpaceX IPO Filing Revealed About Starlink's Big Ambitions](https://longbridge.com/en/news/287245743.md)
- [FACTBOX-IPO-bound SpaceX's board is stacked with Musk empire loyalists](https://longbridge.com/en/news/287206089.md)
- [INSTANT VIEW-SpaceX files long awaited IPO, creating a fresh AI play](https://longbridge.com/en/news/287124128.md)
- [ANALYSIS-Why SpaceX's mega IPO may not signal a broader rebound in listings](https://longbridge.com/en/news/287215490.md)
- [GRAPHIC-Major takeaways from Magnificent Seven's AI-fueled earnings](https://longbridge.com/en/news/287224928.md)